13.2 ASCCP Risk-Based Management & Breast Cancer Screening

ASCCP Risk-Based Management Consensus Guidelines

In 2019, the American Society for Colposcopy and Cervical Pathology (ASCCP) transitioned from rigid result-based algorithms to risk-based management guidelines. Management is determined by calculating the patient's estimated risk of harboring high-grade cervical precancer (CIN 3+, including CIN 3, AIS, and invasive cancer), combining current screening test results with prior screening history.

Clinical Action Thresholds for CIN 3+ Risk

• Immediate Risk ≥60% (Expedited Treatment Threshold): Expedited treatment (loop electrosurgical excision procedure [LEEP] or cold knife conization) without prior confirmatory colposcopic biopsy is preferred; diagnostic colposcopy with biopsy is acceptable. (Expedited treatment is also acceptable for immediate risks between 25% and 59%).
• Immediate Risk ≥4.0% (Colposcopy Threshold): Colposcopic examination with directed cervical biopsies and endocervical sampling is mandatory.
• Immediate Risk <4.0% (Surveillance Thresholds):
  • 5-Year Risk 0.55% to 3.9%: 1-year surveillance interval (repeat co-testing in 12 months).
  • 5-Year Risk 0.15% to 0.54%: 3-year surveillance interval (repeat co-testing in 3 years).
  • 5-Year Risk <0.15%: 5-year surveillance interval (return to routine 5-year screening).

Management of Specific Cytologic & HPV Abnormalities

ASCCP Management of Common Cytologic Abnormalities
├── ASC-US (Atypical Squamous Cells of Undetermined Significance)
│   ├── Reflex hrHPV Negative ──> Repeat Co-testing or Cytology in 3 Years
│   └── Reflex hrHPV Positive ──> Immediate Risk ≥4% ──> Perform Colposcopy
│       └── (Special exception: Age 21-24 ──> Repeat Cytology at 12 Months)
├── LSIL (Low-Grade Squamous Intraepithelial Lesion)
│   ├── Age ≥25 with hrHPV Positive or Unknown ──> Perform Colposcopy
│   ├── Age ≥25 with hrHPV Negative Co-test ──> Repeat Co-testing in 1 Year
│   └── Age 21-24 ──> Repeat Cytology at 12 Months (avoid colposcopy)
├── HSIL (High-Grade Squamous Intraepithelial Lesion)
│   ├── Age ≥25 (Non-pregnant) ──> Expedited Treatment (LEEP) OR Colposcopy
│   └── Age 21-24 or Pregnant ──> Colposcopy Mandatory (NO immediate LEEP)
└── AGC (Atypical Glandular Cells)
    └── ALL Ages ──> Colposcopy + Endocervical Curettage (ECC) MANDATORY
        └── If Age ≥35 (or <35 with AUB/risk factors) ──> ADD Endometrial Biopsy (EMB)

Colposcopy Technique & Transformation Zone

Colposcopy utilizes binocular magnification and 3% to 5% acetic acid solution (which dehydrates cellular cytoplasm, causing abnormal dysplastic cells with high nuclear-to-cytoplasmic ratios to reflect light as acetowhite epithelium) and Lugol's iodine (Schiller test; normal glycogen-rich squamous epithelium stains dark mahogany brown, whereas dysplastic glycogen-depleted cells remain unstained/yellow).

• Transformation Zone (TZ): The critical area between the original squamocolumnar junction (SCJ) and the new SCJ where squamous metaplasia occurs and >90% of cervical neoplasms arise.
• Endocervical Curettage (ECC): Mandatory when the transformation zone is not fully visualized (Type 3 TZ), in evaluation of atypical glandular cells (AGC), or when excisional treatment is being planned.

---

Breast Cancer Screening & Breast Health Awareness

Breast cancer is the most frequently diagnosed non-skin malignancy and the second leading cause of cancer mortality among women in the United States. Early detection via screening mammography reduces breast cancer mortality by identifying asymptomatic, localized tumors at a curable stage.

USPSTF Breast Cancer Screening Guidelines (Average Risk)

• Biennial Screening Mammography for Ages 40 to 74 Years: In 2024, the USPSTF formally updated its breast cancer screening guidelines, lowering the recommended start age from 50 to age 40 years. All average-risk women should undergo biennial (every 2 years) screening mammography from age 40 through 74 years (Grade B recommendation).
• Ages ≥75 Years: Current evidence is insufficient (Grade I statement) to assess the balance of benefits and harms of screening mammography in women aged 75 and older; clinical decisions should incorporate life expectancy (≥10 years), comorbidities, and patient preferences.
• Screening Modality: Digital breast tomosynthesis (3D mammography) or conventional digital mammography (2D). Supplemental screening with breast ultrasound or MRI in women with dense breast tissue without other risk factors remains an area of insufficient evidence (Grade I).

Clinical Breast Examination (CBE) & Breast Self-Awareness

• Routine Screening CBE: The USPSTF concludes that current evidence is insufficient to recommend for or against routine clinical breast examination in average-risk, asymptomatic women. ACOG suggests that clinical breast examination may be offered every 1 to 3 years for women aged 25 to 39, and annually for women aged 40 and older, as part of a shared decision-making discussion.
• Breast Self-Examination (BSE) vs. Breast Self-Awareness: Randomized clinical trials (such as the Shanghai trial) demonstrate that teaching formal, structured, monthly breast self-examination does not reduce breast cancer mortality but doubles the rate of benign breast biopsies and physician visits. Therefore, professional organizations do NOT recommend teaching routine structured BSE. Instead, nurse-midwives promote breast self-awareness—educating women to understand the normal appearance and texture of their breasts and to report any new, persistent changes promptly.
• Red Flag Symptoms Warranting Diagnostic Evaluation: A new discrete, firm, solitary dominant mass; spontaneous, unilateral, single-duct bloody or clear serosanguinous nipple discharge; skin dimpling or retraction; nipple inversion of recent onset; erythema, edema, or "peau d'orange" (suggestive of inflammatory breast cancer); and persistent axillary or supraclavicular lymphadenopathy.

High-Risk Breast Cancer Surveillance

Women with elevated breast cancer risk require enhanced surveillance beginning at a much younger age:

• Risk Assessment Tools: The Gail Model, Tyrer-Cuzick (IBIS) model, and BRCAPRO quantify lifetime breast cancer risk based on age, reproductive history, prior atypical biopsies (lobular carcinoma in situ [LCIS] or atypical ductal hyperplasia [ADH]), and pedigree.
• Annual Screening MRI + Annual Mammography: Recommended for women with a calculated lifetime risk ≥20%, individuals with documented BRCA1 or BRCA2 genetic mutations, first-degree relatives of BRCA carriers who are untested, or women with a history of therapeutic mantle radiation to the chest between ages 10 and 30. Surveillance begins at age 25 to 30 years (or 10 years earlier than the youngest affected first-degree relative), alternating breast MRI and mammography every 6 months.

---